What diseases or symptoms are Besudil/Yilaike mainly used to treat?

Belumosudil mesylate tablets (Belumosudil) is an innovative ROCK2 kinase inhibitor specifically designed for patients with chronic graft-versus-host disease (cGVHD). Chronic GVHD is a common complication after bone marrow or hematopoietic stem cell transplantation. The pathological mechanism involves abnormal activation of the immune system, enhanced inflammatory response, and organ fibrosis. Traditional treatment mainly relies on glucocorticoids or immunosuppressants, but some patients have insufficient response to standard regimens or develop resistance. At this time, besudil becomes an important treatment option.

The drug regulates T cells and immune microenvironment by inhibitingROCK2 signaling pathway, inhibits the excessive release of inflammatory mediators, and reduces tissue fibrosis. This mechanism of action allows it to not only relieve inflammatory symptoms of affected organs such as the skin, mouth, and liver, but also improve damaged functions and improve the quality of daily life of patients. Clinical studies have shown that besudil can be used in patients with chronic GVHD aged 12 years and above, especially those who are ineffective in glucocorticoids or other systemic treatments, providing a new long-term management method for such refractory patients.

During use, the efficacy of besudil is closely related to individualized management. The doctor will develop a dosage plan and follow-up plan based on the patient's symptom location, severity of illness, and previous treatment history. The drug is an oral preparation, which is convenient for long-term use and helps patients adhere to the course of treatment. Compared with traditional immunosuppressants, besudil has a relatively mild side effect spectrum and is easy to manage in the long term, but blood indicators and liver function still need to be monitored regularly to ensure safety.

In general, besudil, as a ROCK2 kinase inhibitor, provides patients with chronic GVHD with a highly targeted and innovative mechanism of treatment option. Its main indication is chronic GVHD that does not respond well to traditional glucocorticoids or immunosuppressive treatments. It can improve the symptoms of inflammation and fibrosis while improving patients' quality of life and provide scientific support for long-term management.

Reference: https://www.drugs.com/pro/rezurock.html